Compare YDDL & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | FATE |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.8M | 125.6M |
| IPO Year | 2024 | 2013 |
| Metric | YDDL | FATE |
|---|---|---|
| Price | $1.21 | $2.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $5.74 |
| AVG Volume (30 Days) | 20.5K | ★ 1.3M |
| Earning Date | 09-29-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $25.83 | N/A |
| Revenue Next Year | $23.91 | N/A |
| P/E Ratio | $40.85 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $0.95 |
| 52 Week High | $16.23 | $3.23 |
| Indicator | YDDL | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 44.29 |
| Support Level | $1.09 | $1.81 |
| Resistance Level | $1.94 | $2.60 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 39.73 | 40.00 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of the Philippines. The company processes raw materials and generates final products that include copper alloy ingots, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap, and industrial recycling. The company operates and manages its business as a single segment and has one operating and reportable segment, trading of recycled scrap metals. Geographically, it generates the majority of its revenue from China.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.